Detailed Review Of Prospects For CymaBay Therapeutics Inc. Stock

A share price of CymaBay Therapeutics Inc. [CBAY] is currently trading at $4.12, up up 5.64%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CBAY shares have gain 28.75% over the last week, with a monthly amount glided 32.90%, and seem to be holding up well over a long-time horizon.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

On 4, August 2022, CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022. In a post published today on Yahoo Finance, CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.

From an analyst’s perspective:

Previously, H.C. Wainwright reaffirmed its Buy rating on August 04, 2020, and elevated its price target to $13. On July 31, 2020, Piper Sandler initiated with a Overweight rating and assigned a price target of $12 on the stock. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $9 on May 26, 2020. SVB Leerink upgraded its rating to a Outperform but $6 remained the price target by the analyst firm on May 12, 2020. Stifel upgraded its rating to Buy for this stock on May 12, 2020, and upped its price target to $8. In a note dated May 12, 2020, ROTH Capital upgraded an Buy rating on this stock but restated the target price of $15.

CymaBay Therapeutics Inc. experienced fluctuations in its stock price throughout the past year between $1.67 and $4.74. Currently, Wall Street analysts expect the stock to reach $10.25 within the next 12 months. CymaBay Therapeutics Inc. [NASDAQ: CBAY] shares were valued at $4.12 at the most recent close of the market. An investor can expect a potential return of 148.79% based on the average price forecast.

Analyzing the CBAY fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.97 points at the first support level, and at 3.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.24, and for the 2nd resistance point, it is at 4.35.

CymaBay Therapeutics Inc. [CBAY] reported earnings per share of -$0.32 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.31/share, meaning a difference of $-0.01 and a surprise factor of -3.20%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.34 per share as compared to estimates of -$0.26 per share, a difference of $-0.08 representing a surprise of -30.80%.

Ratios To Look Out For

A current ratio of 13.70 is a noteworthy aspect of CymaBay Therapeutics Inc. [NASDAQ:CBAY]. Further, the Quick Ratio stands at 10.41, while the Cash Ratio is 10.16.

Transactions by insiders

Insider trading, which has resulted in 1 insider purchases of 51,301 shares and 0 insider sales of 0 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Shah Sujal, Chief Executive Officer, that happened on Jun 06 when 51301.0 shares were purchased. Chief Medical Officer, KIM DENNIS D completed a deal on Jan 19 to buy 20000.0 shares.